Published in Biol Reprod on February 17, 2016
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
DNA repair pathways as targets for cancer therapy. Nat Rev Cancer (2008) 6.69
Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res (2008) 6.46
Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development (2007) 4.80
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
Aberrations of EZH2 in cancer. Clin Cancer Res (2011) 3.13
Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr Opin Genet Dev (2009) 2.63
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
Increasing incidence of breast cancer in family with BRCA1 mutation. Lancet (1993) 2.33
The role of EZH2 in tumour progression. Br J Cancer (2011) 2.33
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A (2009) 2.25
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol (2007) 2.14
Uterine fibroids. N Engl J Med (2013) 1.54
Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol (2008) 1.53
BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res (1999) 1.48
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia (2005) 1.42
Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42
PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet (2014) 1.34
MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget (2014) 1.30
Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res (2003) 1.28
EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin (2013) 1.27
Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27
DNA repair and breast carcinoma susceptibility in women. Cancer (2004) 1.26
Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol (2006) 1.26
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol (2012) 1.24
EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci (2011) 1.23
Immortalization of human uterine leiomyoma and myometrial cell lines after induction of telomerase activity: molecular and phenotypic characteristics. Lab Invest (2002) 1.22
Estrogen receptors and human disease: an update. Arch Toxicol (2012) 1.22
BRCA1 regulates RAD51 function in response to DNA damage and suppresses spontaneous sister chromatid replication slippage: implications for sister chromatid cohesion, genome stability, and carcinogenesis. Cancer Res (2005) 1.21
(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis (2011) 1.14
Differential estrogenic actions of endocrine-disrupting chemicals bisphenol A, bisphenol AF, and zearalenone through estrogen receptor α and β in vitro. Environ Health Perspect (2012) 1.11
Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat (2010) 1.10
Variability in nucleotide excision repair and cancer risk: a review. Mutat Res (2000) 1.09
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ (2011) 1.07
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol (2014) 1.03
DNA repair and nonmelanoma skin cancer in Puerto Rican populations. J Am Acad Dermatol (2003) 1.00
BRCA1: a review of structure and putative functions. Dis Markers (1998) 0.98
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther (2012) 0.98
Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod (2013) 0.97
The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. Reprod Sci (2015) 0.97
Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51. Cancer Treat Rev (2014) 0.96
Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma. Cancer Res (2004) 0.96
EZH2 promotes malignant phenotypes and is a predictor of oral cancer development in patients with oral leukoplakia. Cancer Prev Res (Phila) (2011) 0.96
Gene therapy and uterine leiomyoma: a review. Hum Reprod Update (2006) 0.96
Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest (2015) 0.95
Uterine fibroid: a review. Niger J Med (2004) 0.95
Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. BMC Cancer (2010) 0.94
Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics (2014) 0.93
Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer. PLoS One (2014) 0.92
Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor. Fertil Steril (2003) 0.90
Aberrant expression of HMGA2 in uterine leiomyoma associated with loss of TSC2 tumor suppressor gene function. Cancer Res (2002) 0.90
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. PLoS One (2013) 0.89
EZH2: a pivotal regulator in controlling cell differentiation. Am J Transl Res (2012) 0.89
Is genetic polymorphism of ER-α, CYP1A1, and CYP1B1 a risk factor for uterine leiomyoma? Arch Gynecol Obstet (2010) 0.89
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril (2008) 0.88
Estrogen receptor alpha polymorphism and susceptibility to uterine leiomyoma. Steroids (2006) 0.88
Pulmonary artery smooth muscle cell proliferation and migration in fetal lambs acclimatized to high-altitude long-term hypoxia: role of histone acetylation. Am J Physiol Lung Cell Mol Physiol (2012) 0.87
Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells. Cell Prolif (2013) 0.87
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PLoS One (2014) 0.87
MicroRNA-101 inhibits the metastasis of osteosarcoma cells by downregulation of EZH2 expression. Oncol Rep (2014) 0.87
Targeting histone methyltransferase EZH2 as cancer treatment. J Biochem (2014) 0.87
The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog (2014) 0.87
A new method of histologic dating of human endometrium in the luteal phase. Fertil Steril (1988) 0.86
Increased expression of latent TGF-beta binding protein-1 and fibrillin-1 in human uterine leiomyomata. Mol Hum Reprod (2007) 0.86
MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertil Steril (2014) 0.85
Polycomb repressive complex 2 (PRC2) protein ESC regulates insect developmental timing by mediating H3K27me3 and activating prothoracicotropic hormone gene expression. J Biol Chem (2013) 0.84
Histone methyltransferase EZH2 is transcriptionally induced by estradiol as well as estrogenic endocrine disruptors bisphenol-A and diethylstilbestrol. J Mol Biol (2014) 0.82
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. Cancer Biol Ther (2013) 0.81
Contributions of the RAD51 N-terminal domain to BRCA2-RAD51 interaction. Nucleic Acids Res (2013) 0.80
Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells. Prostate (1999) 0.80
Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: a review. Breast (2014) 0.79
Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis peritonealis disseminata). Pathology (2013) 0.79
Endogenous levels of Rad51 and Brca2 are required for homologous recombination and regulated by homeostatic re-balancing. DNA Repair (Amst) (2013) 0.79
The specific alteration of histone methylation profiles by DZNep during early zebrafish development. Biochim Biophys Acta (2014) 0.78
Identification and characterization of novel human transcripts embedded within HMGA2 in t(12;14)(q15;q24.1) uterine leiomyoma. Mutat Res (2006) 0.78
Genetic polymorphisms of DNA repair gene XRCC1 and risk of uterine leiomyoma. Mol Cell Biochem (2009) 0.77
Estrogen receptor beta gene polymorphisms and susceptibility to uterine fibroids. Gynecol Endocrinol (2010) 0.77
Breast cancer prevention in BRCA1/2 mutation carriers: a qualitative review. Breast J (2008) 0.77
[Molecular-genetic determinants of the neoplastic process and state-of-the-art treatment of patients with uterine leiomyoma]. Vopr Onkol (2001) 0.76